Orchestra BioMed secured over $111 million in proceeds and capital from strategic transactions, with $71 million from Medtronic and Ligand. They hit FDA milestones for AVIM therapy and BACKBEAT study enrollment criteria. The FDA approved the Virtue SAB U.S. pivotal trial versus paclitaxel-coated balloon. Financial results showed $33.9 million in cash as of June 30, 2025, with $101 million estimated by August 12, 2025.

Orchestra BioMed’s Q2 highlights included $111.2 million in proceeds from strategic transactions. They received $56.2 million from a public offering and $16.2 million from private placements with Medtronic and Ligand. The funds will support key milestones like completing the BACKBEAT study and Virtue Trial enrollment, aiming to reshape clinical standards for hypertensive heart disease and atherosclerotic artery disease.

AVIM therapy, compatible with pacemakers, aims to lower blood pressure and improve heart function. Pilot studies showed reductions in blood pressure and improvements in cardiac function. The FDA granted Breakthrough Device Designation for AVIM therapy in patients with uncontrolled hypertension and increased cardiovascular risk. Virtue SAB, a drug-device combo, delivers sirolimus to treat artery disease, backed by positive clinical data and Breakthrough Device Designation for specific indications.

Financially, Orchestra BioMed reported $35.9 million in cash and marketable securities as of June 30, 2025. They had $15.6 million in cash used for operations during Q2 2025, with $0.8 million in revenue. Research and development expenses were $13.9 million, and the net loss was $19.4 million for the quarter. The company continues to focus on advancing their innovative therapies to market.

Read more at GlobeNewswire: Orchestra BioMed Reports Second Quarter 2025 Financial